Podcast appearances and mentions of komal jhaveri

  • 25PODCASTS
  • 60EPISODES
  • 1h 4mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • May 19, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about komal jhaveri

Latest podcast episodes about komal jhaveri

OncLive® On Air
S13 Ep2: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

OncLive® On Air

Play Episode Listen Later May 19, 2025 49:30


This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with mBC, approximately half of the patients were undertreated, and only half received a CDK4/6 inhibitor (CDK4/6i)-based regimen in the first-line setting. Reasons for undertreatment include concerns about the patient's age, perceived frailty, and underlying health issues. Aging is a heterogeneous process; older patients must receive individualized treatment that is not based solely on their age but on a comprehensive assessment that objectively assesses their overall health and ability to tolerate treatment. This program is designed to help clinicians assess the fitness of older patients with HR+/HER2– mBC, review the efficacy and safety of CDK4/6i in this patient population, and individualize treatment decision-making appropriately. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Today's faculty are: Hope S. Rugo, MD Director, Women's Cancers Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA Professor Emeritus, UCSF Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris. Neil M. Iyengar, MD Associate Attending, Breast Medicine Service Program Lead, MSK Healthy Living Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Adviser: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics. Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health. Editorial Position: npj Breast Cancer, Oncology®. Equity/Ownership: Complement Theory, Bettering Company. Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat's Ribbon of Hope, National Cancer Institute/National Institutes of Health. Contracted Research: Novartis, SynDevRx. Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician, Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center Associate Professor of Clinical Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc. Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

CME in Minutes: Education in Primary Care
Komal Jhaveri, MD, FACP - Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- Metastatic Breast Cancer

CME in Minutes: Education in Primary Care

Play Episode Listen Later Apr 10, 2025 19:18


Please visit answersincme.com/BCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for the management of hormone receptor–positive, HER2-negative metastatic disease. Upon completion of this activity, participants should be better able to: Identify the available TROP2-directed ADCs for management of HR+, HER2- metastatic breast cancer (mBC); Outline the efficacy and safety of available and emerging TROP2-directed ADCs for HR+, HER2- mBC; and Apply personalization factors to help identify the optimal therapy for each individual patient with HR+, HER2- mBC.

Breast Cancer Update
5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Breast Cancer Update

Play Episode Listen Later Mar 22, 2025 16:10


Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Research To Practice | Oncology Videos
ER-Positive Metastatic Breast Cancer | 5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Mar 21, 2025 16:10


Featuring an interview with Dr Komal Jhaveri, including the following topics: Emerging treatment options for advanced ER-positive breast cancer (0:00) Burstein H. Emerging treatment options for advanced ER+ breast cancer. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01 Discussant. Elacestrant real-world progression-free survival for adult patients with ER-positive, HER2-negative advanced breast cancer: A retrospective analysis using insurance claims in the United States (7:28) Swallow E et al. Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: A retrospective analysis using insurance claims in the United States. San Antonio Breast Cancer Symposium 2024;Abstract P3-10-08. Ongoing clinical trials involving oral SERDs (9:03) Kaklamani V et al. ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-20. An adjuvant endocrine-based therapy study of camizestrant (AZD9833) in ER+/HER2- early breast cancer (CAMBRIA-2). NCT05952557 Bardia A et al. ELEGANT: Elacestrant versus standard endocrine therapy in women & men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-21. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:48) Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract CME information and select publications

Oncology Today with Dr Neil Love
5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Mar 21, 2025 16:10


Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Breast Cancer Update
5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Breast Cancer Update

Play Episode Listen Later Mar 4, 2025 18:31


Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Research To Practice | Oncology Videos
5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Mar 3, 2025 18:31


Featuring an interview with Dr Komal Jhaveri, including the following topics: Imlunestrant, an oral selective estrogen receptor degrader (SERD), with and without abemaciclib for ER-positive, HER2-negative advanced or metastatic breast cancer (0:00) Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2024;[Online ahead of print]. Abstract Rugo HS et al. Elacestrant abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2024; Abstract PS7-07. Elacestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1-mutated tumors: Subgroup analyses from the Phase III EMERALD trial by duration of prior endocrine therapy with a CDK4/6 inhibitor and in clinical subgroups (7:40) Bardia A et al. Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res 2024;30(19):4299-309. Abstract Pharmacokinetics and safety of imlunestrant in patients with hepatic impairment (11:25) Wang XA et al. Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment. San Antonio Breast Cancer Symposium 2024;Abstract P4-10-07. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:15) Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract CME information and select publications

Oncology Today with Dr Neil Love
5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Feb 28, 2025 18:31


Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

OncLive® On Air
S12 Ep15: Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

OncLive® On Air

Play Episode Listen Later Feb 17, 2025 14:58


In today's episode, supported by Genentech, we had the pleasure of speaking with Komal Jhaveri, MD, FACP, about the clinical use of inavolisib (Itovebi) for patients with hormone receptor (HR)–positive, PIK3CA-mutated, locally advanced or metastatic breast cancer. Dr Jhaveri is section head of the Endocrine Therapy Research Program, clinical director of the Early Drug Development Service, and the Patricia and James Cayne Chair for Junior Faculty at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Jhaveri discussed the importance of having a PI3K inhibitor available for the treatment of patients with HR-positive metastatic breast cancer, advice for managing inavolisib-related adverse effects, and best practices for early biomarker testing in patients with breast cancer.

Research To Practice | Oncology Videos
Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Jan 3, 2025 120:37


Featuring perspectives from Dr Matthew P Goetz, Dr Sara A Hurvitz, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Hurvitz (12:21) Incorporation of CDK4/6 Inhibitors into the Management of HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Wander (34:36) Evolving Role of PI3K Inhibitors for HR-Positive mBC Harboring PIK3CA Mutations — Dr Goetz (57:58) Clinical Utility of AKT Inhibitors for Patients with Progressive HR-Positive mBC — Dr Jhaveri (1:15:52) Oral SERDs (Selective Estrogen Receptor Degraders) for HR-Positive mBC — Dr Kaklamani (1:37:24) CME information and select publications

Oncology Today with Dr Neil Love
Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Jan 3, 2025 120:36


Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/SABCS2024/HRPosEndocrine).

Breast Cancer Update
Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer

Breast Cancer Update

Play Episode Listen Later Jan 3, 2025 120:36


Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024.

Oncology Brothers
INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer

Oncology Brothers

Play Episode Listen Later Nov 25, 2024 23:24


Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study. Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations. Key topics discussed include: •⁠  ⁠Overview of the INAVO120 study and its significance •⁠  ⁠The unique patient population targeted in the study •⁠  ⁠Key findings, including the impressive improvement in progression-free survival (PFS) •⁠  ⁠Side effects and management strategies for patients •⁠  ⁠The importance of genetic testing in treatment decisions Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #OncologyBrothers #BreastCancer #ENAVOLacib #PIK3CA #CancerResearch #MedicalPodcast #Oncology Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Research To Practice | Oncology Videos
Hormone Receptor-Positive Metastatic Breast Cancer | Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities

Research To Practice | Oncology Videos

Play Episode Listen Later Nov 19, 2024 56:49


Featuring perspectives from Dr Komal Jhaveri and Dr Hope S Rugo, including the following topics: Introduction: PI3K/AKT/PTEN Pathway and Resistance to Endocrine Therapy (0:00) First-Line Therapy for HR-Positive Metastatic Breast Cancer (mBC) Harboring PI3K/AKT/PTEN Mutations (7:04) Treatment Options for Recurrent mBC with PI3K/AKT/PTEN Mutations (24:11) Beyond the Guidelines Survey (35:36) Faculty Case Presentations (51:27) CME information and select publications

Breast Cancer Update
Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities

Breast Cancer Update

Play Episode Listen Later Nov 19, 2024 56:48


Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.

Oncology Today with Dr Neil Love
Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities

Oncology Today with Dr Neil Love

Play Episode Listen Later Nov 18, 2024 56:48


Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PI3KAKTPTENmBC24).

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 2, 2024 74:57


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 2, 2024 74:57


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 2, 2024 74:57


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 2, 2024 74:57


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 2, 2024 74:57


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 2, 2024 74:57


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 2, 2024 74:57


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Oct 2, 2024 74:57


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

Oncology Overdrive
Breast Cancer Drug Development with Komal Jhaveri, MD

Oncology Overdrive

Play Episode Listen Later Jul 11, 2024 21:54


In this episode, host Shikha Jain, MD, speaks with Komal Jhaveri, MD, about breakthroughs in breast cancer treatment, where the field is evolving with anti-body drug conjugates and more. •    Welcome to another exciting episode of Oncology Overdrive 1:17 •    About Jhaveri 1:21 •    The interview 1:41 •    How did you get into this highly specialized field? […] How did you become a breast oncologist and find yourself at Memorial Sloan Kettering?  2:07 •    As a breast oncologist, what has really excited you in the breast cancer space over the last decade?  5:02 •    What do you think is going to happen in the next five to twenty years? Where do you think breast cancer treatment is going to evolve?  13:44 •    Do you think AI is going to have a big impact on how we treat patients? 17:47 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 19:52 •    How to contact Jhaveri 20:34 •    Thanks for listening 21:32 Komal Jhaveri, MD, is a breast oncologist & early drug development specialist, clinical director of the early drug development service, and section head of the endocrine therapy research program at Memorial Sloan Kettering Cancer Center (MSK). We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Jhaveri can be reached at her office 646-888-5157, or via email jhaverik@mskcc.org.  Disclosures: Jain reports no relevant financial disclosures. Jhaveri reports she is the principal investigator for Genentech's INAVO120 trial at MSK and co-chair globally.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Komal Jhaveri, MD, FACP - Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2024 89:35


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SBE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Komal Jhaveri, MD, FACP - Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 3, 2024 89:38


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SBE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Komal Jhaveri, MD, FACP - Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 3, 2024 89:38


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SBE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Komal Jhaveri, MD, FACP - Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2024 89:35


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SBE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Komal Jhaveri, MD, FACP - Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2024 89:35


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SBE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Komal Jhaveri, MD, FACP - Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 3, 2024 89:38


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SBE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

Research To Practice | Oncology Videos
Hormone Receptor-Positive Breast Cancer | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Hormonal Therapy for Hormone Receptor-Positive Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 20, 2024 122:23


Featuring perspectives from Dr Harold J Burstein, Ms Kelly Fischer, Dr Komal Jhaveri and Ms Melissa Rikal, including the following topics: Introduction (0:00) The Utility of Genomic Assays in Treatment Decision-Making for HR-Positive, HER2-Negative Localized Breast Cancer (10:21) The Role of CDK4/6 Inhibitors in Therapy for HR-Positive Breast Cancer (37:18) Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer (mBC) (1:04:27) Alpelisib and Capivasertib in Treatment for HR-Positive mBC (1:28:40) NCPD information and select publications

Research To Practice | Oncology Videos
ER-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Mar 11, 2024 38:13


Featuring an interview with Dr Komal Jhaveri, including the following topics: Case: A woman in her mid 50s with ER-positive, HER2-low (IHC 1+) metastatic breast cancer with an ESR1 mutation (0:00) Case: A woman in her late 40s with ER-positive, HER2-low ESR1 wild-type metastatic breast cancer who received imlunestrant on a clinical trial (7:25) Case: A woman in her early 60s with a history of localized breast cancer who received imlunestrant and abemaciclib on a trial for newly diagnosed metastatic breast cancer after disease progression on endocrine therapy (12:03) Beyond the Guidelines: A survey of clinical investigator perspectives on the current and future role of oral SERDs (selective estrogen receptor degraders) for ER-positive metastatic breast cancer (17:35) CME information and select publications

Research To Practice | Oncology Videos
ER-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Play Episode Listen Later Mar 11, 2024 40:38


Featuring a slide presentation and related discussion from Dr Komal Jhaveri, including the following topics: Role of ESR1 mutations in sensitivity and resistance to endocrine therapy in patients with ER-positive metastatic breast cancer (0:00) Efficacy and safety of oral SERDs in patients with ER-positive metastatic breast cancer (13:26) Similarities and differences among available and investigational oral SERDs for ER-positive metastatic breast cancer (24:21) CME information and select publications

Oncology Today with Dr Neil Love
Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Mar 11, 2024 37:32


Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayOralSERDsmBC23).

Breast Cancer Update
Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer

Breast Cancer Update

Play Episode Listen Later Mar 11, 2024 37:37


Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.

OBR Peer-Spectives
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer

OBR Peer-Spectives

Play Episode Listen Later Feb 1, 2024 12:04


CDK4/6 inhibitors “have really been a game changer” in metastatic breast cancer, according to Komal Jhaveri, MD, clinical director for early drug development and section head for endocrine therapy research at Memorial Sloan Kettering in New York City. However, optimal treatment strategies have been complicated by a lack of head-to-head trials. Dr. Jhaveri speaks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles, about how “practice patterns have slightly shifted” despite challenges in assessing efficacy across regimens and approaches. Dr. Jhaveri also discusses her work on the INAVO120 study, which found a benefit in adding a PI3K inhibitor to the combination of CDK4/6 inhibitors and hormone therapy. The trial reported a “monstrously important clinical hazard ratio,” according to Dr. Figlin, and may help clarify best practices moving forward.

Research To Practice | Oncology Videos
HER2-Negative Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Localized HER2-Negative Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Dec 28, 2023 121:47


Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics: Introduction (0:00) Role of Genomic Assays in Treatment Decision-Making for Localized ER-Positive, HER2-Negative Breast Cancer — Dr Goetz (6:03) Integration of Ovarian Function Suppression into the Management of Breast Cancer in  Premenopausal Patients — Dr Burstein (33:34) Role of CDK4/6 Inhibitors and Other Novel Agents in Therapy for  ER-Positive Localized Breast Cancer — Dr Hurvitz (52:35) Optimizing the Use of Neoadjuvant and Adjuvant Therapy for Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:16:18) Emerging Role of Circulating Tumor DNA Evaluation in the Management of Breast Cancer — Dr Pusztai (1:42:03) CME information and select publications

Research To Practice | Oncology Videos
ER-Positive Metastatic Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of ER-Positive Metastatic Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Dec 21, 2023 120:27


Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics: Introduction (0:00) Optimal Integration of CDK4/6 Inhibitors into the Management of ER-Positive Metastatic Breast Cancer (mBC) — Dr Kaklamani (7:00) Novel Strategies to Overcome Resistance to Endocrine Therapy — Dr Jhaveri (26:20) Current Role of Antibody-Drug Conjugates in the Management of ER-Positive mBC — Dr Rugo (1:00:09) Current and Future Role of Selective Estrogen Receptor Degraders (SERDs) in the Management of ER-Positive mBC — Prof Bidard (1:28:59) Novel Therapies Under Investigation for Patients with ER-Positive mBC — Dr Hamilton (1:40:50) CME information and select publications

Research To Practice | Oncology Videos
Prostate Cancer | Current Approaches and Future Strategies in Oncology: A Multitumor Educational Symposium in Partnership with Florida Cancer Specialists & Research Institute

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 27, 2023 58:43


Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Role of Hormonal Therapy in Prostate Cancer Management — Dr Smith (1:50) Clinical Questions and Cases (13:18) Evidence-Based Use of Other Therapeutic Approaches in Metastatic Castration-Resistant Prostate Cancer — Dr Morgans (26:08) Clinical Questions and Cases (38:01) CME information and select publications

Research To Practice | Oncology Videos
Chronic Lymphocytic Leukemia | Current Approaches and Future Strategies in Oncology: A Multitumor Educational Symposium in Partnership with Florida Cancer Specialists & Research Institute

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 27, 2023 53:56


Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Chronic Lymphocytic Leukemia (CLL): Considerations for Front-Line Treatment — Dr Kahl (1:48) Treatment of Relapsed/Refractory CLL; Novel and Investigational Strategies — Dr Chanan-Khan (35:38) Clinical Questions and Cases (49:58) CME information and select publications

Research To Practice | Oncology Videos
ER-Positive Breast Cancer | Current Approaches and Future Strategies in Oncology: A Multitumor Educational Symposium in Partnership with Florida Cancer Specialists & Research Institute

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 27, 2023 59:30


Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) ER-Positive Breast Cancer — Dr Burstein (3:57) Clinical Questions and Cases (16:47) Selection and Sequencing of Treatment for Relapsed ER-Positive Metastatic Breast Cancer — Dr Jhaveri (33:32) Clinical Questions and Cases (46:02) CME information and select publications

Research To Practice | Oncology Videos
Non-Small Cell Lung Cancer | Current Approaches and Future Strategies in Oncology: A Multitumor Educational Symposium in Partnership with Florida Cancer Specialists & Research Institute

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 27, 2023 61:44


Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Non-Small Cell Lung Cancer Targeted Therapy — Dr Riely (4:09) Non-Small Cell Lung Cancer: Immunotherapeutic and Other Novel Strategies — Dr Wakelee (32:23) CME information and select publications

Research To Practice | Oncology Videos
Colorectal and Gastroesophageal Cancers | Current Approaches and Future Strategies in Oncology: A Multitumor Educational Symposium in Partnership with Florida Cancer Specialists & Research Institute

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 27, 2023 62:50


Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Gastroesophageal Cancers — Dr Philip (1:42) Colorectal Cancer — Dr Bekaii-Saab (32:56) CME information and select publications

Research To Practice | Oncology Videos
Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 26, 2023 150:31


Featuring perspectives from Dr Komal Jhaveri, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O'Shaughnessy, Dr Hope S Rugo and Prof Peter Schmid, including the following topics: Long-Term Management of HER2-Positive Breast Cancer Introduction (0:00) Management of CNS-only disease progression in patients with HER2-positive metastatic breast cancer (2:27) Synergy between tucatinib and HER2-targeted antibody-drug conjugates (5:24) Management of trastuzumab deruxtecan–related adverse events (7:41) Patient selection for and practical implementation of postadjuvant neratinib (13:23) Faculty presentation: Dr Krop (16:26) Optimizing the Management of ER-Positive Localized Breast Cancer Ovarian function suppression to preserve fertility and prevent premature ovarian insufficiency; interrupting adjuvant hormonal therapy to attempt pregnancy (24:56) Selection of patients for adjuvant tamoxifen monotherapy (29:05) Utility of genomic assays in the neoadjuvant setting; management of node-positive disease in postmenopausal patients with low-risk Recurrence Scores® (33:35) Selection between abemaciclib and ribociclib in the adjuvant setting (36:45) Potential utility of circulating tumor DNA assessment in breast cancer (41:58) Faculty presentation: Dr Kalinsky (46:36) Considerations in the Care of Patients with ER-Positive Metastatic Breast Cancer Preference of CDK4/6 inhibitor in the metastatic setting (56:42) Sequencing of trastuzumab deruxtecan in ER-positive, HER2-low metastatic breast cancer (59:00) Faculty presentation: Dr Jhaveri (1:06:39) Novel and Emerging Strategies for ER-Positive Metastatic Breast Cancer Selection of therapy for ER-positive metastatic breast cancer progressing on a CDK4/6 inhibitor; future role of capivasertib (1:19:31) Faculty presentation: Dr Rugo (1:30:39) Evolving Clinical Decision-Making for Localized Triple-Negative Breast Cancer (TNBC) Management of localized TNBC; selection of patients for adjuvant Olaparib (1:46:10) PARP inhibitor tolerability (1:51:55) Faculty presentation: Dr O'Shaughnessy (1:55:31) Recent Advances in the Treatment of Metastatic TNBC (mTNBC) Selection of therapy for triple-negative metastatic breast cancer; sequencing of trastuzumab deruxtecan in ER-negative, HER2-low disease (2:11:08) Faculty presentation: Prof Schmid (2:18:03) CME information and select publications

Research To Practice | Oncology Videos
ER-Positive and Triple-Negative Breast Cancer | Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 1 of a 3-Part Series

Research To Practice | Oncology Videos

Play Episode Listen Later Feb 24, 2023 63:18


Featuring perspectives from Dr Komal Jhaveri, including the following topics: •      Case: A premenopausal woman in her early 40s with a 5.8-cm, ER/PR-positive, HER2-negative infiltrating lobular carcinoma and microscopic sentinel node involvement — Arielle Heeke, MD (11:58) •      Case: A premenopausal woman in her early 40s with a 3.1-cm ER/PR-positive, HER2-negative localized invasive ductal carcinoma (IDC) and a Recurrence Score® of 18 — Alan B Astrow, MD (14:51) •      Case: A woman in her late 50s with ER/PR-positive, HER2-negative, microsatellite stable, BRCA1/2 wild-type, metastatic IDC with PALB2 mutation who receives palbociclib/letrozole and zoledronic acid — Shaachi Gupta, MD, MPH (19:37) •      Case: A postmenopausal woman in her early 60s with de novo ER/PR-positive, HER2-low (IHC 1+) metastatic IDC after disease progression on abemaciclib/letrozole and alpelisib/fulvestrant — Zanetta S Lamar, MD (29:32) •      Case: A premenopausal woman in her mid 30s with ER/PR-positive, HER2-negative IDC receiving neoadjuvant chemotherapy and goserelin, now with sexual dysfunction — Laila Agrawal, MD (34:48) •      Case: A woman in her mid 60s with ER/PR-positive, HER2-low bone-only metastatic IDC on endocrine therapy alone since 2001, now experiencing asymptomatic disease progression (ESR1 variant, AKT1 mutation on liquid biopsy) — Philip L Brooks, MD (45:55) CME information and select publications

Breast Cancer Update
Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 1 of a 3-Part Series

Breast Cancer Update

Play Episode Listen Later Feb 24, 2023 63:17


Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Komal Jhaveri, moderated by Dr Neil Love.

CCO Oncology Podcast
HER2-Positive Breast Cancer: Current Approaches for Quality Care

CCO Oncology Podcast

Play Episode Listen Later Jul 28, 2022 39:32


In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes: Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and riskSequencing available therapies for patients with HER2-positive metastatic disease, including new data on first- and second-line therapy and how to manage patients with central nervous system metastasesManaging common adverse events associated with HER2-targeted therapyPresenters:Erika P. Hamilton, MDDirector, Breast and Gynecologic Cancer Research ProgramDrug Development UnitSarah Cannon Research InstituteInvestigatorTennessee OncologyNashville, TennesseeKomal Jhaveri, MDAssistant Professor of MedicineWeill Cornell Medical CollegeAssociate Attending PhysicianBreast Medicine ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkSee full program:  https://bit.ly/3oBdd45

Our MBC Life
S04 E10 - ER Progression and Resistance: Causes, Consequences, and Hope

Our MBC Life

Play Episode Listen Later May 5, 2022 64:28


About 80% of breast cancers are ER+, meaning that the cancer cells have estrogen receptors, and estrogen is likely to make them grow. Here's the good news/bad news story for ER+ MBC patients. First, the good news: there are a number of effective medications that either reduce available systemic estrogen or block its ability to stimulate cancer growth. The bad news: over time, ER+ cancers develop resistance to these medications, resulting in cancer progression and signaling the need for a new treatment. Fortunately, there is more good news: the best minds in cancer research are on the case. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists  Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance Thanks for listening!More info is available on our website:www.ourmbclife.org Got something to share? Feedback?Email:  ourmbclife@sharecancersupport.orgSend us a voice recording via email or through speakpipe on our website.  Follow us on Facebook, Instagram, and Twitter @ourmbclife.

ASCO Guidelines Podcast Series
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer Guideline Update

ASCO Guidelines Podcast Series

Play Episode Listen Later Apr 19, 2022 9:36


An interview with Dr. Fabrice André from Institute Gustave Roussy in Paris, France, and Dr. Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, NY, authors on “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.” This updated guideline provides precise guidelines on previously endorsed genomic assays and recommendations on the use of new biomarkers to guide endocrine therapy and chemotherapy in patients with ER-positive HER2-negative tumors, and for those with HER2-positive or triple-negative breast cancer. Read the full guideline at www.asco.org/breast-cancer-guidelines.   TRANSCRIPT Brittany Harvey: Hello and welcome to the ASCO guidelines podcast series brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the world of cancer care. You can find all the shows including this one asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Fabrice André from Institut Gustave Roussy in Paris, France, and Dr. Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, NY, authors on “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.” Thank you for being here Dr. André and Dr. Jhaveri. Dr. Fabrice André and Dr. Komal Jhaveri: Thank you. Brittany Harvey: First, I'd like to note that ASCO takes great care in the development of guidelines and ensuring that the ASCO conflict of interest policies follow each guideline. The full conflict of interest information for this guideline panel is available online with the publication of the guideline in the Journal of Clinical Oncology. Dr. André, do you have any relevant disclosures that are directly related to this guideline. Dr. Fabrice André: No. Brittany Harvey: Thank you. And Dr. Jhaveri, do you have any relevant disclosures that are related to this guideline topic? Dr. Komal Jhaveri: No. Brittany Harvey: Great, then let's talk about the content of this guideline update. So, Dr. Jhaveri, what prompted the update to the biomarkers for adjuvant endocrine therapy and chemotherapy in early-stage breast cancer, and what is the scope of this guideline update? Dr. Komal Jhaveri: So, since the biomarker guideline published in 2016, there were several new publications that came out between January 2016 and October 2021 that provided perspectives on the use of some of the genomic assays broadly, or specifically in women based on menopausal status, age or number of lymph nodes. Additionally, new biomarkers such as programmed cell death receptor ligand 1 or PD-L1, stromal TILs, circulating tumor DNA, or circulating tumor cells, or new applications, like extended endocrine therapy have also been developed. So, this updated guideline provides precise guidelines on previously endorsed genomic assays and also provides recommendations on the use of new biomarkers to guide endocrine therapy and chemotherapy in ER-positive HER2-negative, HER2-positive, and triple negative breast cancer. Brittany Harvey: Great. Thank you for setting the stage for this guideline. So, then Dr. André, I'd like to review the key recommendations of the guideline for our listeners. So, starting with, which biomarkers should be used to guide decisions on adjuvant endocrine and chemotherapy for patients with newly diagnosed ER-positive HER2-negative breast cancer? Dr. Fabrice André: Thank you. So, when we are focusing on a newly diagnosed patient with ER-positivity HER-2 negative in the context of the question about deciding on chemotherapy. First, the 21 gene recurrence score should be used in patients with node-negative and in patients with 1-3 node positive who are postmenopausal. In premenopausal, this test will be used only in patients with node-negative. The second test that is recommended is the MammaPrint 70-gene signature. And here the recommendation is to use this test if the patient is older than 50 and is node-negative or 1-3 node-positive. If the patient is 50 years or younger, the clinician should not use this test. Then also a recommendation is that the clinician could use the 12 gene risk score EndoPredict if the patient is postmenopausal and has breast cancer node negative or 1-3 positive-node. And finally, for the genomic test for the patient, the doctor could use PAM50. If the patient is postmenopausal and has breast cancer that is node-negative. Something new in this recommendation is the recommendation that the clinician could use Ki67. If the patient is postmenopausal and has stage I-II breast cancer with very specific recommendations on the cut off for positivity. Brittany Harvey: Great. Thank you for reviewing those recommendations, Dr. André, and highlighting the new Ki67. So, then, in your introduction, Dr. Jhaveri, you discuss the application of assays for extended endocrine therapy. So, which biomarkers should be used to guide decisions regarding extended endocrine therapy for patients with ER-positive HER2-negative breast cancer? Dr. Komal Jhaveri: Thank you. So, a quick word about extended endocrine therapy. I think extended adjuvant endocrine therapy, which is beyond five years of primary endocrine therapy, has certainly demonstrated improved outcomes, however, with modest absolute benefit and added toxicity and tolerability issues. Furthermore, while extended endocrine therapy is endorsed by clinical practice guidelines, clear guidance on individualized approaches to optimize patient selection for prolonged endocrine regimens, also remains limited. And this really underscores the need for prognostic and predictive information from genomic assays that can help guide this important clinical question we face. One such example that has now borne out has been the breast cancer index and really collected evidence from now five studies supports the prognostic and predictive utility of this assay, such that if a patient has node-negative or one to three positive nodes, and has been treated with five years of primary endocrine therapy, to guide decisions about extended endocrine therapy, the clinician may offer Breast Cancer Index with either tamoxifen or aromatase inhibitors or tamoxifen, followed by an aromatase inhibitor. Brittany Harvey: Great, thank you, Dr. Jhaveri. So, then, Dr. André, which biomarkers should be used to guide decisions on adjuvant therapy for early-stage HER2-positive breast cancer or triple-negative breast cancer? Dr. Fabrice André: Well, first, we have to be sure that we are good at defining HER2-positive breast cancer and triple-negative breast cancer. So, it's always good to remind colleagues to have quality control assessment in place for HER2, estrogen receptor, and progesterone receptor stainings. So far, when it's about predicting the benefit of adjuvant chemo or trastuzumab, there is no genomic test that is recommended in patients with HER2-positive or triple-negative breast cancer. Brittany Harvey: Great, thank you. So, then, Dr. Jhaveri, what recommendations did the expert panel make regarding emerging biomarkers? Dr. Komal Jhaveri: When we're talking about emerging biomarkers, we're referring to stromal TILs, we're referring to PD-L1, circulating tumor cells, and circulating tumor DNA. And while there is a lot of emerging data, currently, clinicians should not be utilizing these new biomarkers to guide decisions about adjuvant endocrine therapy or chemotherapy, as we do not have sufficient evidence to support their use. Brittany Harvey: Great and that's important for clinicians to know. So, then finally, Dr. André, in your view, how will these updated guideline recommendations impact both clinicians and patients? Dr. Fabrice André: So, we know Komal mentioned this at the beginning that now there is a very large amount of new publications, new data coming every day in the field of cancer. So, the only way for clinicians to deliver the best treatments for patients is to have the right guidelines with the right methodology, and ASCO is really putting in place a very rigorous methodology to deliver guidelines. And this is the best way to be sure that all patients will have access to the best decision by the doctor. So guidelines are also here to decrease the disparities in terms of the expert decision, and any patient in the world can have access to the best decision, thanks to guidelines delivered by ASCO and all the colleagues of the panel that worked very hard to deliver these guidelines. Brittany Harvey: Excellent! Well, thank you both so much, and the entire expert panel for your work to update these guidelines, and for taking the time to speak with me today, Dr. André and Dr. Jhaveri. Dr. Komal Jhaveri: Thank you. Dr. Fabrice André: Thank you, Brittany. Brittany Harvey: Thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast Series. To read the full guideline go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines in interactive resources in the free ASCO guidelines app available in iTunes or Google Play Store. If you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO the mention of any product or service organization activity or therapy should not be construed as an ASCO endorsement.

Research To Practice | Oncology Videos
Breast Cancer | Proceedings from a symposium in partnership with NCOA and SCOS

Research To Practice | Oncology Videos

Play Episode Listen Later Mar 4, 2022 63:04


Proceedings from a symposium in partnership with NCOA and SCOS. Featuring perspectives from Drs Virginia Borges and Komal Jhaveri on recent advances and real-world implications in breast cancer. CME information and select publications

Hematologic Oncology Update
Recent Advances and Real-World Implications in Chronic Lymphocytic Leukemia and Lymphomas — With Dr Ian Flinn and Dr Ann LaCasce (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Hematologic Oncology Update

Play Episode Listen Later Mar 4, 2022 63:33


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Hematologic Oncology Update
Recent Advances and Real-World Implications in Multiple Myeloma — With Dr Natalie Callander and Dr S Vincent Rajkumar (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Hematologic Oncology Update

Play Episode Listen Later Mar 4, 2022 60:26


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Breast Cancer Update
Recent Advances and Real-World Implications in Breast Cancer — With Dr Virginia Borges and Dr Komal Jhaveri (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Breast Cancer Update

Play Episode Listen Later Mar 4, 2022 63:04


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Prostate Cancer Update
Recent Advances and Real-World Implications in Genitourinary Cancers — With Dr Robert Dreicer and Dr Elisabeth Heath (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Prostate Cancer Update

Play Episode Listen Later Mar 4, 2022 57:08


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Gastrointestinal Cancer Update
Recent Advances and Real-World Implications in Gastrointestinal Cancers — With Dr Howard Hochster and Dr Wells Messersmith (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Gastrointestinal Cancer Update

Play Episode Listen Later Mar 4, 2022 65:18


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Lung Cancer Update
Recent Advances and Real-World Implications in Lung Cancer — With Dr Ramaswamy Govindan and Dr Melissa Johnson (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Lung Cancer Update

Play Episode Listen Later Mar 4, 2022 81:12


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Gastrointestinal Cancer Update
Recent Advances and Real-World Implications in Gastrointestinal Cancers — With Dr Howard Hochster and Dr Wells Messersmith (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Gastrointestinal Cancer Update

Play Episode Listen Later Mar 4, 2022 65:18


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Gastrointestinal Cancer Update
Recent Advances and Real-World Implications in Gastrointestinal Cancers — With Dr Howard Hochster and Dr Wells Messersmith (Proceedings from a Symposium in Partnership with NCOA and SCOS)

Gastrointestinal Cancer Update

Play Episode Listen Later Mar 4, 2022 65:18


Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Research To Practice | Oncology Videos
Breast Cancer | Dissecting the Decision: Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive, HER2-Negative Metastatic Breast Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later May 30, 2019 147:02


  A roundtable discussion with Drs Neelima Denduluri, Shom Goel, Erika Hamilton, Komal Jhaveri, Ruth M O'Regan and Sara M Tolaney featuring review of patterns of care survey results, presentation of relevant data sets and moderated panel discussion. Module 1: Biology of the CDK4/6 Pathway and Pharmacology of the CDK4/6 Inhibitors Abemaciclib, Ribociclib and Palbociclib General medical oncologist survey results (0:00) Presentation of relevant data sets — Dr Goel (2:27) Panel discussion (11:02) Module 2: Management of ER-Positive, HER2-Negative Metastatic Breast Cancer (mBC) in Postmenopausal Patients General medical oncologist survey results (17:17) Presentation of relevant data sets — Dr Denduluri (18:54) Panel discussion (21:53) Module 3: Role of CDK4/6 Inhibitors for Premenopausal Patients with ER-Positive, HER2-Negative mBC General medical oncologist survey results (30:38) Presentation of relevant data sets — Dr Jhaveri (31:31) Panel discussion (41:59) Module 4: Site and Extent of Metastases, Including CNS Involvement, and Outcomes with CDK4/6 Inhibitors; Predictors of Response to Therapy General medical oncologist survey results (1:5:57) Presentation of relevant data sets — Dr Tolaney (1:7:28) Panel discussion (1:19:33) Module 5: Pathophysiology of Class- and Agent-Specific Toxicities and Optimal Management Strategies General medical oncologist survey results (1:37:04) Presentation of relevant data sets — Dr Hamilton (1:38:12) Panel discussion (1:52:15) Module 6: Mechanisms of Resistance to CDK4/6 Inhibitors, Treatment Beyond Disease Progression and Novel Strategies with Combinations General medical oncologist survey results (2:00:03) Presentation of relevant data sets — Dr O'Regan (2:01:39) Panel discussion (2:06:26) Select publications